0000000000790845
AUTHOR
Amélie Cransac
showing 4 related works from this author
Évaluation des coûts médicamenteux évités grâce aux inclusions des patients atteints d’hémopathie maligne dans les essais cliniques
2020
Resume Introduction Les essais cliniques (EC) sont indispensables pour evaluer l’efficacite et l’innocuite de nouveaux traitements. Ils peuvent representer une mesure d’economie grâce a la fourniture des medicaments par le promoteur. Objectif L’objectif de cette etude est d’evaluer les couts evites en medicament hors-GHS ou sous Autorisation Temporaire d’Utilisation (ATU) par l’inclusion d’un patient dans un EC d’Hematologie. Materiels et methodes C’est une etude de cout, retrospective, monocentrique, observationnelle. La perspective de l’etude est elargie du point de vue de l’assurance maladie obligatoire. Nous avons inclus les EC d’Hematologie ayant eu au moins une dispensation entre 2007…
Adherence to immunomodulatory drugs in patients with multiple myeloma
2018
Background Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two indirect methods to measure IMID adherence in multiple myeloma patients: a specific questionnaire and the medication possession ratio (MPR). Another aim was to explore this specific questionnaire for the assessment of IMID adherence in multiple myeloma patients. Methods All consecutive multiple myeloma patients, with at least two consecutive dispensations of thalidomide, lenalidomide or pomalidomi…
Self‐management of immunomodulatory drug treatment in multiple myeloma patients
2019
Objective Immunomodulatory drugs (IMIDs: thalidomide, lenalidomide and pomalidomide) are widely used in patients with multiple myeloma (MM). The aim of our study was to validate a questionnaire to evaluate the self-capacity of MM patients to manage IMID treatment including side effects. Methods We used a method adapted from the recommendations of the European Organisation for Research and Treatment of Cancer (EORTC) to validate a French questionnaire for patients with MM treated with IMIDs. Results The face validity was evaluated in 15 patients and the construct validity in 56 patients. For discriminant validity, two groups were constituted by gender and depending on whether they had a prev…
Safety of ninety-minute daratumumab infusion.
2020
Purpose Daratumumab is the first anti-CD38 monoclonal antibody of the class approved for recurrent and refractory multiple myeloma. Grade 3 and 4 Infusion-Related Reactions (IRRs) are frequent during the first and second infusions. Due to the risks associated with severe IRRs, daratumumab is systematically administered over a period of 3.5 hours. The main objective of this study was to evaluate the safety of a 90-minute daratumumab infusion from the third infusion. Patients and methods All patients who had received two or more doses of daratumumab in monotherapy or in combination with standard infusion rates were included. We excluded patients enrolled in clinical trials. For the rapid infu…